Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almonertinib in Resectable Stage III EGFR+ NSCLC
NCT04685070Phase 2Active, not recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Started Dec 2021; status: active, not recruiting.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04685070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04685070.